POLICY

Prepared I.V. piggybacks will be compounded in accordance with established guidelines, utilizing log records for preparations, storage recommendations, thorough labeling, and quality control mechanisms.

PROCEDURE

1. Log records - kept on file in black binder labeled "COMPOUNDED I.V. PIGGYBACK SOLUTIONS" (see attached form) and kept on file for 3 years with the following information:
   a. Compounding directions
   b. RLANRC Lot number
   c. Date
   d. Medication compounded
   e. Ingredients
      (1) Manufacturer's lot number(s)
      (2) Manufacturer's expiration date(s)
   f. Amount made
   g. Technician's and Pharmacist's initials
2. Labeling
   a. Name and concentrations of ingredients contained in the sterile injectable product.
   b. Expiration date
   c. RLANRC Lot Number
   d. Instructions for storage and handling.
   e. All hazardous agents shall bear a special label which states "Chemotherapy-of Properly" or "Hazardous-Dispose of Properly."
3. Quality Control
   a. Refrigerator will be maintained between 2°-8°C (35°-46°F)
   b. Freezer will be maintained between -25° to -10°C (-13° to 14°F).
   c. Room temperature will be maintained between 20°-24°C (68°-75°F).
   d. Expiration dates will be monitored daily.
   e. Stock rotation will ensure solutions are being use in order prepared.
4. Recall Procedure
   a. If a product of a compounded sterile product is recalled by a

manufacturer or the compounded sterile product is suspected of lacking integrity, potency, quality, or labeled strength, the IV pharmacist, on the day of notification of the recall or suspected compounded sterile product, will immediately refer to the sterile compounding log and retrieve the recalled product or suspected compounding product if available.

b. A list of patients will be generated that have received the product and the clinician(s) notified of the recalled product or suspected sterile product.
c. If the compounded sterile product is still available, the suspected product will be retrieved and discarded.
d. Patients who received the compounded product will be monitored as applicable depending on the recall.